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Malignant mesothelioma is a tumour with a poor prognosis (Walz
and Koch, 1985). The development of mesothelioma is associated
with an occupational exposure to asbestos fibres in most patients
(Mossman et al, 1996). The pathogenesis of malignant mesothe-
lioma is still far from clear but there is considerable evidence that
reactive oxygen and nitrogen species (ROS and RNS, respec-
tively) play an important role in the pathogenesis of this disease
(Kamp and Weitzman, 1999). Asbestos fibres increase the genera-
tion of RNS and the levels of nitrotyrosine, a marker of NO related
cell damage, at least in rat pleural mesothelium (Tanaka et al,
1998; Kamp and Weitzmann, 1999; Kinnula, 1999). It can there-
fore be hypothesized that the expression of nitric oxide synthases
might be upregulated in asbestos-related pleural diseases.
NO is generated from L-arginine by nitric oxide synthase
(NOS) which is present in three isoforms, endothelial NOS
(eNOS), neuronal NOS (nNOS) and inducible NOS (iNOS)
(Kobzik et al, 1993; Beckman and Koppenol, 1996; Wink and
Mitchell, 1998). The synthesis of the constitutive forms of NOS,
eNOS and nNOS, is dependent on the calcium concentration of the
cell. Inducible NOS is stimulated by several cytokines, such as
IL-1, IL-4, IL-10, IL-12, INF-g, TNF-a and b and by asbestos
fibres in a variety of cells (Thomas et al, 1994; Quinlan et al, 1998;
Tanaka et al, 1998; Kamp and Weitzmann, 1999; Kinnula, 1999).
Nitric oxide is a free radical, which reacts with molecules, such as
superoxide, thiols and metalloproteins thus locally modifying
biological reactions of the cell (Beckman and Koppenol, 1996;
Wink and Mitchell, 1998). One of the most potential toxic
compounds generated in these reactions is peroxynitrite, which
can contribute to the formation of other reactive nitrogen 
metabolites in the cell.
Inducible NOS can be detected in multiple cells such as
macrophages, bronchial epithelial cells, alveolar type II epithelial
cells, fibroblasts and pleural mesothelial cells (Kobzik et al, 1993;
Thomas et al, 1994; Moilanen et al, 1997; Quinlan et al, 1998;
Tanaka et al, 1998). The NOS family of proteins also plays an
important role in many pathophysiological conditions. The expres-
sion of iNOS is increased in inflammatory diseases, such as
asthma (Belvisi et al, 1995; Li, 1997) and interstitial lung diseases
(Saleh et al, 1997). Nitrotyrosine is a marker of NO-mediated cell
injury, and it is accumulated in idiopathic pulmonary fibrosis
(Saleh et al, 1997) and at least in pleural mesothelium of asbestos
exposed rats (Choe et al, 1998; Tanaka et al, 1998).
Nitric oxide production may also lead to DNA damage and thus
promote carcinogenesis (Ambs et al, 1997; Kamp and Weitzman,
1999). This is especially interesting with asbestos fibres since they
have been shown to cause NO generation, induction of iNOS and
contribute to mesothelial cell damage by reactive nitrogen species
(Choe et al, 1998; Tanaka et al, 1998). Asbestos fibres are geno-
toxic, they cause formation of 8-hydroxyguanosine, a marker of
DNA damage. This effect has been shown to be attenuated by
NAME, a specific inhibitor of NOS (Chao et al, 1996; Chen et al,
1996). Inducible NOS has also been shown to be expressed in
many tumours such as breast, lung, prostate, gynaecological and
colon carcinomas and in B-cell chronic lymphocytic leukemias
(Thomsen et al, 1994; Thomsen et al, 1995; Ambs et al, 1998a;
Ambs et al, 1998b; Klotz et al, 1998; Zhao et al, 1998). We are not
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aware of any studies on iNOS or other forms of nitric oxide
synthases in human healthy pleura or malignant mesothelioma.
Given the suggested role of NO in asbestos induced pleural
disorders, carcinogenesis and tumour progression, we investigated
the expression of iNOS in normal healthy and reactive pleural
mesothelium and malignant pleural mesothelioma. Five pleural
samples containing non-inflamed and non-neoplastic mesothe-
lium, four cases containing inflamed reactive mesothelium and 38
cases of malignant mesotheliomas were stained with two anti-
bodies to iNOS. Furthermore, 25 metastatic pleural adenocarci-
nomas were included in the study material to test whether any
differences could be found in the iNOS immunoreactivity between
such tumours and mesotheliomas with different progenitor cell
type, pathogenesis and tumour growth characteristics. Since NO
has been suggested to influence apoptosis and angiogenesis we
also determined the extent of apoptosis in mesotheliomas by
TUNEL and also immunostained the slides with an antibody to
FVIII. The mRNA and protein expression of iNOS was further
assessed in four malignant mesothelioma cell lines (M14K,
M25K, M28K and M38K) and a nonmalignant human
transformed mesothelial cell line (Met5A) in culture.
MATERIALS AND METHODS
Histological material
Altogether 38 malignant mesotheliomas, 25 pleural metastatic
adenocarcinomas, four cases of inflamed mesothelium and five
cases originating from peripheral lung tissue containing non-
neoplastic and non-inflamed pleura were retrieved from the files
of the Department of Pathology, Oulu University Hospital between
1976–1997. All the material had been fixed in 10% buffered
formalin and embedded in paraffin. Malignant mesotheliomas
were subclassified into epithelial, sarcomatoid and biphasic
subtypes according to the criteria given by AFIP (Battifora and
McCaughet, 1994). Metastatic adenocarcinomas consisted of
tumours originating from lung, breast, kidney and liver. Clinical
data such as the sex, age and survival of the patients was obtained
from the hospital records. In the mesothelioma group the mean age
was 62.2 ± 10.4 years. There were 5 women and 33 men. The
mean survival in the mesothelioma group was 15.7 ± 27.3 months.
Immunohistochemical stainings for iNOS
A rabbit polyclonal antibody against iNOS (sc-651) was
purchased from Santa Cruz Biotechnology (Santa Cruz
Biotechnology Inc, Santa Cruz, CA) and a mouse monoclonal
anti-iNOS antibody, (N-32320) from Transduction Laboratories
(Transduction Laboratories, Lexington, KY). According to the
manufacturers, both antibodies recognize mouse, rat and human
iNOS.
The immunostainings with the poly- and monoclonal iNOS
antibodies were performed as follows. Before application of the
primary antibodies, the sections were heated in a microwave oven
in 10 mM citric acid monohydrate, pH 6.0, for 10 minutes. The
dilution for the primary antibody for the poly- and monoclonal
iNOS antibody was 1:200 and 1:60, respectively. The immuno-
staining was performed using the Histostain-Plus Bulk Kit (Zymed
Laboratories Inc, South San Francisco, CA) and the chromogen
used was aminoethyl carbazole (AEC) (Zymed Laboratories Inc).
Negative control stainings were carried out by substituting PBS or
non-immune mouse or rabbit serum for the primary antibodies.
The intensity of the immunostainings with all the antibodies
was evaluated by dividing the staining reaction in four groups.
1 = weak cytoplasmic staining intensity, corresponding
approximately to less than 25% of the staining intensity in
neutrophils;
2 = moderate cytoplasmic staining intensity, corresponding
approximately to 25–50% of the staining intensity in
neutrophils;
3 = strong cytoplasmic staining intensity, corresponding
approximately to 50–75% of the staining intensity in
neutrophils;
4 = very strong cytoplasmic staining intensity, corresponding
approximately to 75% or more of the staining intensity in
neutrophils.
The quantity of the immunostaining was evaluated as follows:
0 = no positive immunostaining;
1 = < 25% of tumour cells showing cytoplasmic positivity;
2 = 25–50% of tumour cells showing cytoplasmic positivity;
3 = 50–75% of tumour cells showing cytoplasmic positivity;
4 = > 75% of tumour cells showing cytoplasmic positivity.
A combined score for the immunostaining, based on both
qualitative and quantitative immunostaining was composed by
adding both the qualitative and quantitative score which was then
divided in three main groups; – = no immunostaining (score 0);
+ = weak immunostaining (scores 1–4); ++ = strong
immunostaining (scores 5–8).
Immunostaining of FVIII related antigen
A polyclonal rabbit anti-human antibody to FVIII-related antigen
was purchased from Dako (Dakopatts, Denmark). The primary
antibody was applied on the slides for 1 hour with a dilution of
1:50. After this a secondary anti-rabbit antibody (Dako,
Dakopatts, Denmark) was applied followed by the ABC-complex.
The colour was developed with diaminobenzidine and hydrogen
peroxide. The vascular density was estimated as the number of
positively stained blood vessels in one high power field. In each
tumour section a minimum of 10 high power fields were analysed.
3¢-end labelling of DNA in apoptotic cells
In order to detect apoptotic cells, in situ labelling of the 3¢-ends of
the DNA fragments generated by apoptosis-associated endonucle-
ases was performed using the ApopTag in situ apoptosis detection
kit (Oncor, Gaithersburg, MD, USA). The sections, after being
dewaxed in xylene and rehydrated in ethanol, were incubated
with 20 mg/ml Proteinase K (Boehringer Mannheim GmbH,
Mannheim, Germany) at room temperature for 15 minutes. The
endogenous peroxidase activity was blocked by incubating the
slides in 2% hydrogen peroxide in PBS, pH 7.2. The slides were
then treated with terminal transferase enzyme and digoxigenin-
labelled nucleotides after which anti-digoxigenin-peroxidase solu-
tion was applied on the slides. The colour was developed with
diaminobenzidine after which the slides were lightly counter-
stained with haematoxylin. Cells were defined as apoptotic if the
whole nuclear area of the cell labelled positively. Apoptotic bodies
were defined as small positively-labelled globular bodies in the
cytoplasm of the tumour cells which could be found either singlyor in groups. To estimate the apoptotic index (the percentage of
apoptotic events in a given area), apoptotic cells and bodies in
tumour cells were counted in 10 high power fields (HPFs) and this
figure was divided by the number of tumour cells in the same
HPFs.
Cultured cells
Mesothelioma cell lines M14K, M25K, M28K and M38K were
originally established from the tumour tissue of untreated patients
(Pelin-Enlund et al, 1990). Human non-malignant transformed
pleural mesothelial cells (Met5A) were obtained from American
Type Culture Collection (Rockville, MD). The cells were grown in
RPMI 1640 cell culture medium supplemented with 10% fetal
calf serum, 100 U/ml penicillin, 100 mg/ml streptomycin, and
0.03% L-glutamine (all from LTI, Life Technologies, Paisley, UK)
at 37°C in 5% CO2 atmosphere. For immunocytochemistry the cell
pellets were fixed in 10% neutral formalin overnight, after which
the formalin was removed, and melted 2% agar was laid over
the pellets. The agar blocks were further embedded in paraffin.
Four mm thick sections were cut from the cell blocks and stained
for the polyclonal anti-iNOS antibody as previously described.
RT-PCR for iNOS
Expression of iNOS mRNA in cultured cells was investigated by
using reverse transcription polymerase chain reaction (RT-PCR).
The oligonucleotide primers were selected according to cDNA
sequence data published earlier (Geller et al, 1993). Total cellular
RNA was extracted from the cells using a kit for RNA isolation
(RNEasy, Qiagen, Hilden, Germany). One mg of RNA was treated
with DNAase I (Pharmacia, Biotech, Milwaukee, WI) at 37°C for
10 min and at 75°C for 10 min to eliminate possible DNA contam-
ination of the samples and reverse transcribed with 100 U of
Moloney murine leukaemia virus reverse transcriptase (Gibco
BRL, Paisley, UK) and 5 pmol of antisense primer (5¢-GGTGCT-
GCTTGTTAGGAGGTCAAGTAAAGGGC-3¢) at 42°C for 45 min
in a 20 ml reaction mixture containing 1 U RNase inhibitor
(5 Prime – >3 Prime, Boulder, CO). The cDNA was PCR-ampli-
fied in a thermal cycler (Perkin-Elmer Cetus, Norwalk, CT) using
1 U of DNA polymerase (Dynazyme, Finnzymes, Finland) and
5 pmol of sense primer (5¢-TGCCTGGCAAGCCCAAGGTC-
TATGTTCAGGAC-3¢) in a 100 ml reaction volume containing
1.5 mM MgCl2. The thermal profile involved 35 cycles of denatu-
ration at 94°C for 50 sec, primer annealing at 64°C for 50 sec, and
extension at 72°C for 1 min 30 sec. PCR products were elec-
trophoresed in an ethidium bromide-stained 2% agarose (Seakem,
Rockland, ME) gel and visualised under UV-light. The amplifica-
tion product was 500 base pairs (bp) in length. Negative controls
were established in each experiment by substituting the RNA
sample with water and by leaving the reverse transcriptase enzyme
out of the RT-reaction. A549 cells were used as positive controls in
each experiment (Zhao et al, 1998).
Statistical analysis
SPSS for Windows (Chicago, IL, USA) was used for statistical
analysis. The significance of the associations were determined
using Fisher’s exact probability test, correlation analysis and two-
tailed t-test. The survival analysis was performed by the Kaplan-
Meyer curve and significance of associations were tested by
the log-rank test. Probability values P≤0.05 were considered
statistically significant.
RESULTS
Mesothelial cells in four out of five cases in non-neoplastic and
non-inflamed healthy pleural tissue showed no immunoreactivity
for iNOS (Fig. 1A) (Table 1). In one case a few, scattered iNOS
positive mesothelial cells could be observed amongst a majority of
negatively stained cells (not shown). In contrast, all cases with
inflamed reactive mesothelium showed iNOS positivity and in one
case, the expression was strong. Malignant pleural tissues also
showed positive immunostaining for iNOS in most of the cases;
28/38 (74%) of malignant pleural mesotheliomas (Fig. 1B, C) and
24/25 (96%) of metastatic pleural adenocarcinomas were iNOS
positive (Fig. 1 D, E) (Table 1). The immunoreactivity for iNOS
was diffuse intracytoplasmic and finely granular.
Of the non-neoplastic cells, strong immunoreactivity for iNOS
could be observed in lung alveolar macrophages and in
macrophages of the tumour tissue. Also neutrophils expressed
strong positivity for iNOS while lymphocytes were negative.
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Table 1 Immunohistochemical expression of iNOS in non-neoplastic mesothelium, mesotheliomas and metastatic adenocarcinomas studied with the poly- and
monoclonal iNOS antibody.
INOS Non-neoplastic Reactive Epithelial Sarcomatoid Biphasic Metastatic
Polyclonal mesothelium mesothelium mesothelioma mesothelioma mesothelioma adenocarcinoma
–4 0 2 6 2 1
+1 31 7 4 2 1 8
++ 0 1 5 0 0 6
Total 5 4 24 10 4 25
INOS
Monoclonal*
–4 0 6 7 2 3
+1 31 2 2 2 2 1
++ 0 1 3 0 0 1
Total 5 4 21 9 4 25
*= Due to exhaustion of the blocks immunostaining of some cases with the monoclonal antibody are missingNitric oxide synthase in mesothelioma 883
British Journal of Cancer (2000) 83(7), 880–886 © 2000 Cancer Research Campaign
Positivity was also observed in endothelial cells and in fibroblasts
of the tumour stroma. There was no significant difference in the
number of iNOS positive stromal macrophages and neutrophils
between mesotheliomas and carcinomas. Furthermore, the number
of positive stromal macrophages and neutrophils was not associ-
ated with the iNOS-positive mesotheliomas and/or carcinoma
cases (data not shown).
Two iNOS antibodies were used to test the reproducibility of the
iNOS immunostaining in the material. Generally, the polyclonal
iNOS antibody gave a stronger immunoreaction compared with
the monoclonal iNOS, whereas monoclonal iNOS antibody
showed less background. There was a significant association
between iNOS expression between the results obtained with the
two iNOS antibodies (P = 0.002) in malignant mesotheliomas and
in the whole material consisting also of the adenocarcinomas
(P < 0.001). With both antibodies, there were significantly more
Figure 1 A. Immunostaining for iNOS in normal pleural samples.
Mesothelial cells lining the healthy pleura tissue are negative for iNOS.
Diffusely scattered macrophages seen in the subpleural tissue are, however,
positive. B. Globular cytoplasmic immunoreactivity for iNOS can be seen in
tumour cells of an epithelial type of malignant mesothelioma with the
polyclonal iNOS antibody C. Another epithelial mesothelioma case stained
with the monoclonal iNOS antibody. The tumour cells show diffuse
cytoplasmic positivity for iNOS. D. A pleural metastatic adenocarcinoma
showing positive cytoplasmic immunoreactivity for the monoclonal iNOS
antibody in tumour cell. E. Another metastatic adenocarcinoma showing only
weak positivity for the polyclonal iNOS anitbody. Positively stained reactive
cells (arrowheads) can be seen among the neoplastic tumour cell islands.
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often iNOS negative mesotheliomas than metastatic adeno-
carcinomas (P = 0.021 with the poly- and P < 0.001 with the
monoclonal antibody). Sarcomatoid mesotheliomas displayed
significantly more often no immunostaining compared to epithe-
lial or mixed mesotheliomas (P = 0.001 with the poly- and
P = 0.023 with the monoclonal antibody). No association was
found between iNOS immunoreactivity and patient survival
(P = 0.30 and P = 0.16 for the poly- and monoclonal antibody, by
the log rank test). In order to test the reproducibility of the results,
they were evaluated by another pathologist (PP) using the same
scoring system. The association between the evaluations of the
two observers was significant (P < 0.0001, Fisher’s exact test).
The average apoptotic index in mesotheliomas was 1.07%
(range 0.0–4.8%) and the average number of vessels/HPF 8.7
(range 1–58). There was no statistically significant association
between iNOS expression and apoptosis or vascular density in
mesotheliomas (P = 0.07 and P = 0.29 for the monoclonal and
P = 0.95 and P = 0.25 for the polyclonal antibody). No association
was found between patient survival and iNOS immunoreactivity in
malignant mesotheliomas (P = 0.251 and P = 0.170 for the 
poly- and monoclonal antibody, log rank).
In metastatic adenocarcinomas the mean apoptotic index was
1.73% (range 0.07–7.01%) and the average vascular density
6.88/HPF (range 1.38–20.40). There was no statistically signifi-
cant difference in apoptosis or vascular density as compared with
mesotheliomas (P = 0.12 and P = 0.33, respectively). There was no
statistically significant association between iNOS expression and
apoptosis or vascular density in metastatic adenocarcinomas
(P = 0.73 and P = 0.37 for the monoclonal and P = 0.17 and
P = 0.82 for the polyclonal andibody).
To further confirm the synthesis of iNOS in malignant mesothe-
lioma cells iNOS mRNA and protein expression was assessed in
four malignant mesothelioma cell lines and also in transformed
mesothelial cells (Met5A) in culture. Expression of iNOS mRNA
was found in all five cell lines studied (Figure 2). Similarly,
immunohistochemical expression of iNOS for the polyclonal anti-
body could be found in all cell lines investigated. By showing
iNOS mRNA synthesis and immunohistochemical iNOS expres-
sion in all these cell lines these additional experiments confirmed
the finding that neoplastic mesothelial cells are capable of
synthesizing iNOS also in vitro.
DISCUSSION
This study shows that the majority of malignant mesotheliomas
express strong iNOS immunoreactivity. In contrast, its expression
is infrequently found in non-neoplastic healthy mesothelium.
When comparing iNOS reactivity in histologically different
subtypes of mesothelioma, epithelial and biphasic subtypes
expressed significantly more often iNOS positivity than the sarco-
matoid subtype suggesting that its expression is especially a trait
of the epithelial subtype.
The pathogenesis of mesothelioma is associated with asbestos
fibres but a remarkable part of mesotheliomas (15%) can develop
without a previous exposure to asbestos fibres (Jaurand, 1997).
The present study with adenocarcinomas metastasized to pleura
showed at least the same intensity of iNOS as was found in pleural
mesotheliomas. Thus other factors than asbestos fibres probably
cause the induction of iNOS in mesothelioma. Most likely these
factors include increased levels of cytokines and growth factors
which are produced by a variety of cells present in these condi-
tions. Interestingly, our cell culture studied showed that malignant
mesothelioma cells are able to synthesize iNOS also in vitro. This
indirectly indicates that iNOS expression in malignant meso-
thelioma could be autocrinically regulated. In fact, mesotheliomas
have been shown to be able to synthesize some interleukins and
growth factors such as IL-6, IL-8 and to a lesser extent IL-1 and
TNFa (Monti et al, 1994; Galffy et al, 1999).
Increased expression of iNOS has been found both in the
tumour cells and in adjacent nonmalignant cells such as reactive
macrophages and endothelial cells of the tumour tissue (Thomsen
et al, 1994; Thomsen et al, 1995; Ambs et al 1998a; Ambs et al,
1998b; Klotz et al, 1998). Our results agree with these findings and
show that both malignant mesothelioma and adenocarcinoma
tumour cells as well as non-malignant stromal cells of both
tumours are capable of iNOS synthesis. Most metastatic adeno-
carcinomas consisted of cases originating from breast and lung. A
high frequency of iNOS expression in them is paradoxical since
iNOS expression has been suggested to inhibit the metastatic
potential of tumour cells (Xie and Fidler, 1998). On the other hand
our results are consistent with recent experimental studies on
iNOS in rat mesothelium (Choe et al, 1998; Tanaka et al, 1998)
and suggest that the secretion of iNOS inducing cytokines may be
higher in pleural tissues than in other metastatic sites.
Strong expression of iNOS in malignant pleural tumours
suggests that NO synthesis may play an important role in the
development and growth of these malignancies. Apoptosis has an
important role in carcinogenesis and tumour progression, and it is
known that NO may be either pro- or anti-apoptotic depending on
the cell type, NO concentration and/or experimental conditions
(Shen et al, 1998). NO also leads to the accumulation of wild type
p53 and bax resulting in increased apoptosis (Ambs et al, 1998a).
Accumulation of wild type p53, on the other hand, leads to inhibi-
tion of iNOS synthesis; thus there is a negative feedback loop
between NO and iNOS synthesis (Ambs et al, 1998a). Also the
family of bcl-2 proteins regulates or modulates apoptosis caused
by NO. Bcl-2, for example, inhibits NO induced apoptosis (Kim
et al, 1998). In mesotheliomas and mesothelial cell lines bcl-2
expression is infrequent while bax expression is frequently found
(Segers et al, 1994; Narasimhan et al, 1998; Soini et al, 1999). NO
has also been reported to inhibit APO-1/FAS mediated apoptosis
(Mannick et al, 1997; Dimmeler et al, 1998). In our study we could
500 bp —
A549
A549-
H 2 O
M38K
M28K
M25K
M14K
Met5A
Figure 2 The RT-PCR experiment for the mesothelioma cell lines. Lane 1:
The positive control (A549 lung carcinoma cell line). Lane 2: Negative
control, reverse transcriptase omitted. Lane 3: Negative control, substituting
the RNA sample with water. Lanes 4–8: M38K, M28K, M25K and M14K
mesothelioma cell lines and Met5A mesothelial cells. All these cell lines as
well as A549 positive control cell line show a clear 500 bp band for iNOS
mRNA.Nitric oxide synthase in mesothelioma 885
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not find any significant association between apoptosis and iNOS
expression. This may reflect the dual influence of NO on apoptosis
and the complex regulation of apoptosis by other factors such as
the bcl-2 family proteins.
Expression of iNOS also influences tumour vascularity by
upregulating the synthesis of vascular endothelial growth factor
(VEGF) thus promoting angiogenesis in tumour tissue (Ziche et al,
1997). Inducible NOS expression in mesothelial tumours might
thus serve as a factor promoting tumour growth through stimula-
tion of angiogenesis. In our material of malignant mesotheliomas
there was no significant association between iNOS expression and
vascular density suggesting that iNOS synthesis by mesothelioma
tumour cells does not play a significant role in angiogenesis.
Regulation of angiogenesis is, however, complex and confounded
by various factors, such as the presence of iNOS-synthesizing
stromal cells. In our pleural samples of malignant mesothelioma
there were many reactive macrophages, neutrophils, fibroblasts
and endothelial cells which were shown to express iNOS strongly.
Surely, their presence would further modulate the internal milieu
of the tumours and influence both angiogenesis and apoptosis in
malignant pleural tumours.
In conclusion, our results show prominent expression of iNOS
in malignant mesothelioma and metastatic adenocarcinoma of the
pleura when compared to healthy pleural mesothelium. Also in
vitro malignant mesothelial cell lines could be shown to express
iNOS. This finding suggests that NO synthesis modulates the
growth and progression of these tumours. Contrary to some
previous notions, metastatic adenocarcinomas also expressed
iNOS to a considerable degree. The total effect of iNOS on tumour
behaviour in malignant mesotheliomas is probably a complex
phenomenon where also stromal cells play an important role.
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